These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16680936)

  • 1. Characterization of an anaphylactoid reaction to omalizumab.
    Dreyfus DH; Randolph CC
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):624-7. PubMed ID: 16680936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
    Lin RY; Rodriguez-Baez G; Bhargave GA
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):442-5. PubMed ID: 19927545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
    Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
    J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
    Limb SL; Starke PR; Lee CE; Chowdhury BA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1378-81. PubMed ID: 17936893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
    Cardona R; Ramírez RH; Reina Z; Escobar MF; Morales E
    Biomedica; 2009 Jun; 29(2):181-90. PubMed ID: 20128343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies.
    Quiralte J; Blanco C; Castillo R; Ortega N; Carrillo T
    Ann Allergy Asthma Immunol; 1997 Mar; 78(3):293-6. PubMed ID: 9087155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
    Cruz AA; Lima F; Sarinho E; Ayre G; Martin C; Fox H; Cooper PJ
    Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
    Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
    Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.
    Dreyfus DH
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):624-5. PubMed ID: 18592835
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed allergic reactions to omalizumab: are patients reporting all cases?
    Barry PJ; O'Mahony A; Finnegan C; O'Connor TM
    J Allergy Clin Immunol; 2008 Mar; 121(3):785-6; author reply 786. PubMed ID: 18328902
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.